UNSPSC 51342404: Saquinavir mesilate or mesylate

This classification denotes a protease inhibitor with the molecular formula C38H50N6O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UHB9Z3841A, chemically known as butanediamide, n(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, monomethanesulfonate, but more generally known as saquinavir mesylate, which bears US NIH Compound Identifier 60787.

UNSPSC 51342404 Saquinavir mesilate or mesylate is a Commodity code that nominally targets a specific antiretroviral pharmaceutical, yet recent state and local opportunities tagged under it reflect a wider procurement pattern in emergency response and community health pharmaceuticals and supplies. The code appears in solicitations for naloxone (opioid reversal agents), fire department medical consumables, and generic multi-source pharmaceuticals through cooperative purchasing vehicles, indicating that state and local agencies are using this commodity designation to reach pharmaceutical suppliers across multiple therapeutic categories and delivery channels rather than as a narrow specification for a single active ingredient. Issuing bodies include state health and human services agencies, county health departments, municipal fire departments, and cooperative purchasing alliances serving multiple jurisdictions; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission stand out as state-level repeat participants in recent market engagement.

Recent activity spans Florida, Texas, Minnesota, and Oregon through cooperative arrangements. Representative solicitations include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health delivery; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies including respiratory equipment and cardiac monitoring electrodes for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a sheltered-market set-aside for certified Small Local Business Enterprises; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities, with evaluation weighted 75 percent on price competitiveness and responses due through the ePro procurement system. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs, signaling state interest in alternative pharmacy supply chain models beyond traditional wholesaler arrangements.